Morgan Stanley Raises ZEALAND PHARMA/S (NASDAQ:ZEAL) Price Target to $30.00
ZEALAND PHARMA/S (NASDAQ:ZEAL) had its target price boosted by Morgan Stanley from $29.00 to $30.00 in a report released on Monday morning, BenzingaRatingsTable reports. Morgan Stanley currently has an overweight rating on the stock.
ZEAL has been the topic of several other research reports. Needham & Company LLC restated a buy rating and set a $32.00 price objective (up previously from $29.00) on shares of ZEALAND PHARMA/S in a research report on Thursday, August 15th. Zacks Investment Research cut shares of ZEALAND PHARMA/S from a buy rating to a hold rating in a research report on Saturday, July 27th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. ZEALAND PHARMA/S has a consensus rating of Buy and an average target price of $27.33.
ZEALAND PHARMA/S stock opened at $21.24 on Monday. The firm’s fifty day moving average price is $22.11 and its 200-day moving average price is $19.29. The stock has a market cap of $651.06 million, a P/E ratio of 7.08 and a beta of 1.91. ZEALAND PHARMA/S has a fifty-two week low of $11.51 and a fifty-two week high of $23.55.
An institutional investor recently bought a new position in ZEALAND PHARMA/S stock. Susquehanna International Group LLP bought a new position in ZEALAND PHARMA/S (NASDAQ:ZEAL) during the second quarter, according to the company in its most recent filing with the SEC. The firm bought 15,348 shares of the company’s stock, valued at approximately $331,000. 9.08% of the stock is currently owned by institutional investors.
ZEALAND PHARMA/S Company Profile
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
See Also: Holder of Record
Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.